Abstract
A family is presented in which neurofibromatosis type 2 (NF2) and autosomal dominant hearing loss segregate in an apparently independent way. The presence of the latter condition caused anxiety in all family members at risk for NF2 in whom hearing loss became apparent. Previously, we identified a G → A transition in the donor splice site of exon 5 of the NF2 gene in a family member with proven NF2. As expected, the mutation was present in two other family members who fulfilled the diagnostic criteria for NF2. Four out of five family members at risk for NF2 developed hearing loss. Two of these had the G → A transition. The mutation was absent in the two other individuals with hearing loss and in the fifth family member without hearing loss or other clinical symptoms. In this family, the identification of the underlying NF2 gene mutation excluded NF2 as the cause of hearing loss in two potential carriers of the mutated gene. On the other hand, it enabled the identification of two carriers of the NF2 gene mutation who did not fulfill the diagnostic criteria for NF2. They will have to be monitored very carefully for the development of NF2-associated tumors. The consistent association within this family of a relatively mild clinical phenotype with the NF2 mutation, supports earlier suggestions that intrafamilial variability is small in NF2
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cole WG, Chiodo AA, Lamande SR, Janeczko R, Ramirez F, Dahl H-HM, Chan D, Bateman JF (1990) A base substitution at a splice site in the COL3A1 gene causes exon skipping and generates abnormal type III procollagen in a patient with Ehlers-Danlos syndrome type IV. J Biol Chem 265:17070–17077
Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramsden R, Harris R (1992a) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841–846
Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992b) A clinical study of type 2 neurofibromatosis. Q J Med 84:603–618
Hagiwara Y, Nishio H, Kitoh Y, Takeshima Y, Narita N, Wada H, Yokoyama M, Nakamura H, Matsuo M (1994) A novel point mutation (G-1 to T) in a 5′ splice donor site of intron 13 of the dystrophin gene results in exon skipping and is responsible for Becker muscular dystrophy. Am J Hum Genet 54:53–61
Hogg A, Bia B, Onadim Z, Cowell JK (1993) Molecular mechanisms of oncogenic mutations in tumors from patients with bilateral and unilateral retinoblastoma. Proc Natl Acad Sci USA 90:7351–7355
Koningsmark BW, Gorlin RJ (1976) Genetic and metabolic deafness. WB Saunders Company, Philadelphia, London, Toronto
MacCollin M, Mohney T, Trofatter J, Wertelecki W, Ramesh V, Gusella J (1993) DNA diagnosis of neurofibromatosis 2. Altered coding sequence of the merlin tumor suppressor in an extended pedigree. JAMA 270:2316–2320
MacCollin M, Ramesh V, Jacobt LB, Louis DN, Rubio M-P, Pulaski K, Trofatter JA, Short MP, Bove C, Eldridge R, Parry DM, Gusella JF (1994) Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet 55:314–320
Martuza RL, Eldridge R (1988) Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 318:684–688
Merel P, Hoang-Xuan K, Sanson M, Bijlsma E, Laurent-Puig P, Pulst SM, Rouleau GA, Bonnardel C, Lenoir G, Sterkers JM, Philippon J, Resche F, Mautner VF, Hulsebos T, Aurias A, Delattre O, Thomas G (1995) Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer 12:117–127
Müllenbach R, Lagoda PJL, Welter C (1989) An efficient saltchloroform extraction of DNA from blood and tissues. Trends Genet 5:391
NIH Consensus Development Conference (1994) Consensus statement on acoustic neuroma, December 11–13, 1991. Arch Neurol 51:201–207
Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Bijlsma E, Fashold R, Dumanski J, Jong P De, Parry D, Eldrige R, Aurias A, Delattre O, Thomas G (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515–521
Talerico M, Berget SM (1990) Effect of 5′ splice site mutations on splicing of the preceding intron. Mol Cell Biol 10:6299–6305
Trofatter JA, MacCollin MM, Rutter JL, Murrell JR; Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Haase H, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza L, MacDonald ME, Seizinger BR, Short MP, Buckler AJ, Gusella JF (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791–800
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bijlsma, E.K., Merel, P., Fleury, P. et al. Family with neurofibromatosis type 2 and autosomal dominant hearing loss: identification of carriers of the mutated NF2 gene. Hum Genet 96, 1–5 (1995). https://doi.org/10.1007/BF00214177
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00214177